Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data shows Herceptin plus chemotherapy reduces risk of breast cancer recurrence
November 17th, 2005
Genentech, Inc. (DNA) announced that a joint interim analysis of two phase III trials of Herceptin (trastuzumab) plus chemotherapy showed the addition of Herceptin reduced the risk of breast cancer recurrence by 52% in women with early-stage, operable human epidermal growth factor receptor 2 (HER2)-positive breast cancer, compared to patients who received chemotherapy alone (or a hazard ratio of 0.48). After 4 years of study follow-up, 15% of women treated with Herceptin plus chemotherapy experienced disease recurrence, compared to 33% of women treated with chemotherapy alone. HER2-positive breast cancer is an especially aggressive form of the disease that affects...
Source: Women's Health Weekly (2005-11-17)
|
